L3MBTL1 is a Polycomb group protein that functions as an epigenetic 'reader' of histone methylation marks. It specifically recognizes and binds mono- and dimethylated lysine residues on histone H1b (at Lys-26) and histone H4 (at Lys-20), as well as monomethylated p53 and RB1, leading to chr20 condensation and transcriptional repression 1. The nucleosome context significantly influences L3MBTL1 binding preferences, with full nucleosome substrates providing greater specificity than histone peptides alone 2. Clinically, L3MBTL1 demonstrates relevance across multiple disease contexts. Loss of L3MBTL1 protects against proteotoxicity from misfolded proteins associated with amyotrophic lateral sclerosis and frontotemporal dementia, indicating its role in p53-dependent protein quality control 3. Genome-wide sequencing identified L3MBTL1 as a novel subtype-specific risk gene for frontotemporal lobar degeneration with TDP-43 pathology 4. In lung adenocarcinoma, L3MBTL1 promotes acquired resistance to Osimertinib by regulating chr20 structure and DNA damage response through H4K20me2 binding, competing with 53BP1 1. Higher L3MBTL1 expression correlates with improved breast cancer survival and lower disease recurrence risk 5. Additionally, L3MBTL1 is an imprinted gene whose dysregulation in assisted reproductive technology offspring may influence developmental outcomes through altered methylation patterns 6.